The outbreak of COVID-19 has spread globally since it was first reported in December 2019. Although a variety of clinical manifestations have been reported, the primary reason for morbidity and mortality is hypoxemic respiratory failure.[@bib1] Among hospitalized patients, the published mortality is approximately 5% and is commonly due to refractory respiratory failure and shock.[@bib1] Epidemiological studies report that acute respiratory distress syndrome (ARDS) is common among hospitalized patients with COVID-19 and represents the primary indication for transfer to intensive care units.[@bib1] Recently published guidelines summarize the current recommendations in this rapidly evolving field.[@bib2] As health care systems become increasingly strained, patients with COVID-19 have been admitted to clinical environments where teams and physicians have less experience with ARDS management. This article is intended to provide a pragmatic guide for nonintensivist practitioners who care for patients with ARDS requiring mechanical ventilation (MV). In the absence of MV trials specifically in patients with COVID-19-associated ARDS, the information presented is on the basis of general ARDS trials. We encourage readers to supplement this report with the evolving literature on management of COVID-19-specific ARDS.

Defining ARDS {#sec1}
=============

The Berlin definition of ARDS requires all of the following criteria to be present: (1) symptoms or known clinical insult within 1 week; (2) bilateral opacities on chest imaging, not fully explained by effusions, nodules, or atelectasis; (3) respiratory failure not fully explained by cardiac failure or hypervolemia; (4) arterial oxygen tension (PaO~2~)/fraction of inspired oxygen (FiO~2~) ≤ 300 with positive end expiratory pressure (PEEP) ≥ 5 cm H~2~O. ARDS is further classified according to severity on the basis of arterial blood gas analysis: mild (PaO~2~/FiO~2~ 201-300), moderate (PaO~2~/FiO~2~ 101-200), and severe (PaO~2~/FiO~2~ ≤ 100).[@bib3] ARDS is commonly associated with various infectious, traumatic, and inflammatory conditions, all of which are associated with direct and indirect lung injury; however, a clear pathophysiological mechanism has not been elucidated. Importantly, many patients with these associated conditions will not develop ARDS, suggesting that other pathophysiological mechanisms might play an inciting role. Cardiovascular specialists should be aware of ARDS mimickers, such as heart failure and alveolar hemorrhage.

Advances in supportive strategies, including MV with invasive positive pressure ventilation via endotracheal intubation, have improved outcomes for patients with ARDS; however, mortality remains high. Death might result as a consequence of the underlying illness, refractory hypoxia with or without progressive right ventricular dysfunction, due to multiple organ failure, and/or critical illness complications.

Basic Management of MV in Patients With ARDS {#sec2}
============================================

Although a detailed review of respiratory and MV physiology is beyond the scope of this article, a working understanding of a basic MV pressure waveform is required to understand the stepwise algorithm presented. MV breaths are delivered in either a spontaneous or mandatory mode. In a mandatory mode, the ventilator delivers a set number of breaths per minute, defined as the respiratory rate (RR), regardless of patient effort. These delivered breaths are either volume controlled (VC) whereby a set tidal volume (V~T~) is delivered, or pressure controlled whereby a set inspiratory pressure is delivered. A mandatory VC pressure waveform is presented in [Figure 1](#fig1){ref-type="fig"} . The peak pressure is the highest pressure reached during the respiratory cycle and represents alveolar pressure and resistance to air flow. The plateau pressure is measured during an inspiratory hold, and as such, represents alveolar pressure alone without a resistance component. Isolated high peak pressures can be seen with high resistance in the circuit, bronchospasm, secretions, or endotracheal tube obstruction. High peak and plateau pressures can be seen in parenchymal lung disease (pulmonary edema, ARDS, consolidation, pneumothorax) or secondary to extrapulmonary causes such as pleural effusions, intra-abdominal hypertension, and morbid obesity ([Supplemental Fig. S1](#appsec1){ref-type="sec"}).Figure 1Volume control pressure waveform. PEEP, positive end expiratory pressure.

After inspiration to the peak inspiratory pressure, expiration begins with a predetermined termination signal (flow or pressure) and is characterized by an exponential decrease in airway pressure back to the set PEEP. PEEP improves oxygenation, in part, by mitigating alveolar collapse and increasing the surface area for gas exchange at the alveolar level. The driving pressure is a measure of "lung shear stress" (or cyclical lung strain) and is calculated by subtracting the plateau pressure from the total PEEP.

An algorithmic approach to managing MV in ARDS patients is provided in [Figure 2](#fig2){ref-type="fig"} and the evidence underpinning these recommendations is outlined in [Supplemental Table S1](#appsec1){ref-type="sec"}. When initiating low V~T~ ventilation (LTVV), the first decision involves choosing the mode of MV. VC will deliver a consistent V~T~ and is a reasonable initial choice. Additionally, VC provides the option of setting a 0.2-second inspiratory hold, which gives a real-time plateau pressure measurement. Next, the V~T~ and RR are set, which together determine the total minute ventilation and, therefore, CO~2~ clearance and pH. We suggest using 6 mL/kg predicted body weight V~T~ as an initial setting. The RR is set to meet the patient's minute ventilatory demands while allowing for permissive hypercapnia (ie, pH 7.25-7.35 and PaCO~2~ \> 45 mm Hg). It is reasonable to set the initial RR at 20 breaths per minute and subsequently adjust it to maintain an arterial pH \> 7.25. We suggest setting an initial PEEP of 10 cm H~2~0 and FiO~2~ of 1.0. We suggest weaning the FiO~2~ as soon as possible to target an arterial oxygen saturation of 88%-95% or a PaO~2~ of 55-80 mm Hg.Figure 2Algorithmic approach to MV in patients with ARDS. ARDS, acute respiratory distress syndrome; ECMO, extracorporeal membrane oxygenation; FiO2, fraction of inspired oxygen; H2O, H~2~O; MV, mechanical ventilation; PaO2, arterial oxygen tension; PBW, predicted body weight; PEEP, positive end expiratory pressure; SpO2, arterial oxygen saturation (indirect measurement); VT, tidal volume; VV-ECMO, veno-venous extracorporeal membrane oxygenation.

After MV initiation, the PEEP and FiO~2~ can be adjusted using the ARDSNet PEEP table in [Figure 2](#fig2){ref-type="fig"}. We favour the low PEEP table as the initial strategy because routine higher PEEP strategies have not been associated with improved outcomes. Importantly however, lung injury is often heterogeneous, and clinicians must individualize MV settings accordingly.

Additional MV physiologic goals include monitoring the plateau and driving pressures and avoiding hypervolemia. A plateau pressure \< 30 cm H~2~O is the generally accepted target on the basis of the ARDSNet trial, which showed reduced mortality and increased ventilator-free days in the LTVV arm.[@bib3] Higher pressures are associated with barotrauma and ventilator-induced lung injury. If the plateau pressure exceeds 30 cm H~2~0, the V~T~ should be decreased in 1 mL/kg predicted body weight increments to a minimum of 4 mL/kg. Higher driving pressure (plateau pressure − PEEP) is independently associated with mortality in patients with moderate and severe ARDS.[@bib3] We suggest a driving pressure goal of ≤ 14 mm Hg. Last, a substantial body of evidence supports a conservative fluid management strategy to limit translocation of fluid into the pulmonary interstitium and alveoli.[@bib4] A starting central venous pressure goal of 4-8 mm Hg is reasonable. A lower central venous pressure target can be considered in the more hypoxemic patient, whereas a higher target might be needed if intravascular volume is considered inadequate.

If hypoxemia persists (PaO~2~/FiO~2~ \< 150 and FiO~2~ \> 0.6 with PEEP \> 5 mm Hg) despite optimization of initial LTVV ventilator settings, prone (face down) ventilation has been shown to reduce mortality. Prone positioning involves moving a patient from the supine position to the prone position for 12- to 16-hour cycles per day. This manoeuvre, in part, redistributes perfusion to the better ventilated ventral lung regions, thereby improving gas exchange and oxygenation. Proning results in decreased mortality when initiated early in patients with severe ARDS.[@bib3] Because of the unique patient care required during proning, we suggest consultation with a critical care medicine specialist.

Management in Refractory Cases {#sec3}
==============================

Most patients will be adequately managed with the aforementioned ARDS MV management principles; however, some patients might require advanced treatment for refractory hypoxemia or hypercapnia ([Supplemental Table S1](#appsec1){ref-type="sec"}). These patients should be managed in collaboration with a critical care medicine specialist. It is important to acknowledge that the therapies discussed in this section have not been definitively shown to improve mortality. Continuous neuromuscular blockade (NMB) has the potential benefit of reducing patient-ventilator dyssynchrony and/or work of breathing in patients with ARDS; however, the efficacy of routine NMB in ARDS in randomized trials is conflicting ([Supplemental Table S1](#appsec1){ref-type="sec"}).[@bib5] Because of the potential adverse consequences of NMB, such as intensive care unit weakness, we do not routinely use this in our practice. Indications to consider NMB include patient-ventilator dyssynchrony despite deep sedation and refractory hypoxemia or hypercapnia. Recruitment manoeuvres are transient increases in transpulmonary pressure performed in a deeply sedated patient with a goal to improve oxygenation. Many different protocols exist, such as applying 30-40 cm H~2~O for 20-30 seconds. If oxygenation improves, clinicians can consider increasing PEEP. The main adverse consequences of recruitment manoeuvres are hemodynamic instability and barotrauma such as pneumothorax and should only be performed in consultation with an intensivist. Inhaled prostacyclin or nitric oxide can improve oxygenation by selectively vasodilating well ventilated zones and therefore improving ventilation and perfusion matching. Additionally, these inhaled agents decrease pulmonary vascular resistance and right ventricular afterload. Despite these effects, no clear mortality benefit exists. Less commonly, some patients with ARDS experience refractory hypercapnia and respiratory acidosis (pH \< 7.25). In well sedated and paralyzed patients, ventilatory strategies include increasing the RR and modestly increasing the V~T~ provided that goals of plateau pressures and driving pressures are maintained. These strategies might result in dynamic expiratory flow trapping (auto-PEEP), which can be quantified with an end-expiratory hold.

If patients continue to have refractory hypoxemia or hypercapnia, a consultation for veno-venous extracorporeal membrane oxygenation, depending on regional local availability and patient candidacy, can be considered. The Murray score is composed of 4 variables (hypoxemia, respiratory compliance, chest x-ray findings, and PEEP) and is used to grade the severity of lung injury in ARDS. A Murray score \> 3.0 or a pH \< 7.20-7.25 during optimized therapy, should prompt early notification to the extracorporeal membrane oxygenation team.

Conclusion {#sec4}
==========

Cardiovascular specialists who routinely care for patients requiring MV without ARDS are well positioned to care for critically ill patients. It is imperative that clinicians understand and feel comfortable with the basic management of ARDS, which can be applied to patients with respiratory failure due to COVID-19.
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